Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
–News Direct– Ness Ziona, Israel, January 22, 2024, Kadimastem (TASE: KDST) and iTolerance Inc. announced today that the companies held a preliminary meeting with the INTERACT committee of the U.S Food and Drug Administration (FDA) on January 19th, 2024 regarding the preclinical and clinical development leading toward commercialization of iTOL-102, a potential cure for diabetes…